Equities

Co-Diagnostics Inc

Co-Diagnostics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.29
  • Today's Change0.02 / 1.57%
  • Shares traded73.62k
  • 1 Year change+25.24%
  • Beta-0.8620
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Co-Diagnostics Inc share price to rise to 1.50 in the next year from the last price of 1.29.
High16.3%1.50
Med16.3%1.50
Low16.3%1.50

Earnings history & estimates in USD

On Aug 08, 2024, Co-Diagnostics Inc reported 2nd quarter 2024 losses of -0.14 per share. This result exceeded the -0.34 consensus loss of the one analyst covering the company and exceeded last year's 2nd quarter results by 54.84%.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-5.42%
Co-Diagnostics Inc reported annual 2023 losses of -1.20 per share on Mar 14, 2024.
Average growth rate-92.87%
More ▼

Revenue history & estimates in USD

Co-Diagnostics, Inc. had 2nd quarter 2024 revenues of 2.66m. This bettered the 375.00k estimate of the one analyst covering the company. This was 342.10% above the prior year's 2nd quarter results.
Average growth rate+391.62%
Co-Diagnostics, Inc. had revenues for the full year 2023 of 6.81m. This was 80.09% below the prior year's results.
Average growth rate+8,615.49%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.